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| INTRODUC TI ON
Metabolic reprogramming is a common feature of tumor cell and is characterized by disorders of glucose metabolism, tricarboxylic acid (TCA) cycle, lipid metabolism, cholesterol metabolism, glutamate metabolism, one-carbon metabolism and choline metabolism. [1] [2] [3] [4] [5] Peroxisome proliferator activated receptor (PPAR)
coactivator-1α (PGC1α) is an important transcriptional co-activator in control of mitochondrial function and lipid metabolism, especially fatty acid oxidation (FAO). 6 FAO is the primary pathway for the degradation of fatty acids and it promotes NADPH and ATP production. 7, 8 Abnormal lipid metabolism mediated by FAO plays an important role in tumor progression. 9, 10 High expression of PGC1α is conducive to cancer cell survival during metabolic stress, including oxidative damage, energy crisis and cancer treatment. [11] [12] [13] [14] The evidence indicated that PGC1α might be a metabolic target in cancer therapy.
Notably, PGC1α can interact with numerous transcription factors to mediate mitochondrial function, FAO, gluconeogenesis, reactive oxygem species (ROS) clearance, cell adhesion and migration. [15] [16] [17] [18] PGC1α is involved in regulating the expression of carnitine palmitoyl transferase 1A (CPT1A) and CPT1B in the liver and the heart. [19] [20] [21] [22] CPT1A is a key rate-limiting enzyme in FAO that catalyzes the loading of fatty acyl-groups onto carnitine. 23, 24 Recent studies showed that CPT1A promotes tumor progression in colorectal cancer, prostate cancer and hepatocellular carcinoma. [25] [26] [27] The expression of CPT1A is increased in ovarian cancer and high-grade glioblastoma patients. 28, 29 A previous study indicated that targeting metabolic dependencies of cancer cells might be a selective anticancer strategy and CPT1A has been identified as a target of fatty acid metabolism.
30
Recent studies confirmed that targeting CPT1A-mediated FAO could promote therapy sensitization in several types of cancers. Inhibition of FAO could be a potential therapeutic strategy for lung carcinoma, colon adenocarcinoma and triple-negative breast cancer. [31] [32] [33] Ethyl 2-[6-(4-chlorophenoxy) hexyl] oxirane-2-carboxylate (Etomoxir, ETO), a CPT1A enzymatic inhibitor, can sensitize human metastatic breast carcinoma, colon carcinoma, leukemia and hepatocellular carcinoma to chemotherapy. [34] [35] [36] Nasopharyngeal carcinoma (NPC) is a highly prevalent tumor in southern China, South-East Asia and northern Africa. Due to its anatomical limitations, intensity-modulated radiotherapy is an important treatment strategy against NPC. 37, 38 Our recent study showed that CPT1A is a key molecule in the regulation of FAO and promotes resistance of NPC to radiation. 39 However, the upstream regulatory mechanism of CPT1A in NPC remains unclear.
Therefore, the study and discovery of these upstream regulators of CPT1A might support the elucidation of tumor radiation resistance.
In this study, we illustrate a metabolic feature of active lipid turn- with 10% FBS. Cells were maintained at 37°C in a 5% CO 2 incubator.
| Nasopharyngeal carcinoma tissue array
The NPC tissue array was purchased from Pantomics. The tissue microarray consisted of non-keratinizing undifferentiated NPC (n = 48) and nasopharyngeal inflammation (n = 15). Clinical characteristics of the NPC patients were provided, including age, gender, neck lymph nodule metastasis and EBV-encoded small RNA status. NPC patients were treated with radiation therapy by Co-60.
| Oxygen consumption assay
The extracellular oxygen consumption assay was performed using the MitoXpress Xtra oxygen consumption assay kit (Luxel Bioscience) according to the manufacturer's recommendations.
| Cellular ATP measurement
The intracellular ATP level was measured using the CellTiter-Glo 2.0 Assay kit (G9242; Promega) according to the manufacturer's instructions.
| NADPH/NADP measurement
Intracellular NADPH/NADP levels were assayed using an NADP/ NADPH Quantification Colorimetric Kit (K347-100; Biovision) according to the manufacturer's instructions.
| Cell transfection
Cells were transfected with CEBPB siRNA (GenePharma), PGC1αshRNA (GeneChem), CPT1A shRNA (GeneChem) (Table S1 ), V5-tagged CPT1A and mutCPT1A plasmids (TSINGKE) using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions.
| Western blot analysis and antibodies
Western blot analysis was performed as previously described. 39 The following antibodies were used for western blotting: anti-CPT1A (ab128568; Abcam), anti-PGC1α (ST-1202; Millipore), anti-CEBPB (ab32358, Abcam) and β-actin (A5441; Sigma-Aldrich).
| Immunohistochemistry analysis
Immunohistochemical (IHC) staining was performed as previously described. 41, 42 The results were separately quantified by 2 pathologists from Xiangya Hospital, Changsha, China. The negative to positive patterns (denoted as -to +++) and IHC scores were determined by their staining intensity and positive rate. Anti-CPT1A (ab128568, Abcam) and anti-PGC1α (ST-1202, Millipore) were used to detect the respective proteins.
| Co-immunoprecipitation assay
Cells ( 
| Luciferase reporter assay
A luciferase reporter GV238-CPT1A-promoter (Luc-CPT1A; 
| ChIP assay
ChIP assays were performed with 1 × 10 6 cells by using a ChIP Assay Kit (P2078; Beyotime) according to the manufacturer's instructions.
PCR was performed with primers (Table S2 ) against the promoter of the CPT1A. Anti-CEBPB (ab32358; Abcam) and IgG were used for the ChIP assay and nonspecific IgG was used as a negative control.
| Cell viability assay
Cells were plated in a 96-well plate at a density of 5 × 10 
| Colony formation and radiosensitivity assays
Cells were seeded in 6-well plates in triplicate at 2 × 10 3 (HONE1), 
| Statistical analysis
All statistical calculations were performed with the GraphPad Prism 5 software program (GraphPad Software). The overall survival was estimated using the Kaplan-Meier method. Differences between various groups were evaluated using a 2-tailed Student's t test or Welch's t test and a P-value < 0.05 was considered statistically significant.
For the materials and methods for RNA extraction, quantitative
RT-PCR, immunofluorescence analysis, CPT1 enzymatic activity and CPT1A mutation plasmid (mutCPT1A), see Data S1.
| RE SULTS

| PGC1α overexpressing nasopharyngeal carcinoma cells show a metabolic signature of active fatty acid oxidation
Our previous study showed that lipid metabolism was active in NPC radiation-resistant (CNE2-IR) cells. 39 We 
| A high level of expression of PGC1α
is associated with poor overall survival in nasopharyngeal carcinoma patients after radiation therapy
In a commercially available tissue microarray comprised of non-keratinizing undifferentiated NPC (n = 48) and nasopharyngeal inflammation (n = 15; IHC, Figure 2A ), NPC patients were treated with radiation therapy and followed up. All tumor biopsies were obtained before treatment and patients' clinical characteristics are listed in Table S4 .
The IHC scores indicated that PGC1α was highly expressed in the non-keratinizing undifferentiated NPC compared with samples of nasopharyngeal inflammation ( Figure 2B ). Based on the IHC scores for PGC1α in the non-keratinizing undifferentiated NPC (IHC, Figure 2C ), we set the median score as the cut-off value and divided patients into 2 groups. The patients with high expression of PGC1α (n = 20, median survival time = 60 months) had shorter overall survival compared to patients expressing lower levels of PGC1α (n = 28, survival rate > 50%; Figure 2D ). These observations suggest that high expression of PGC1α corresponds to worse overall survival after radiation therapy in NPC.
| PGC1α positively regulates CPT1A in nasopharyngeal carcinoma
We wondered whether PGC1α had a regulatory effect on CPT1A.
After overexpressing PGC1α in HK1 cells, we observed a significant increase in mRNA, protein levels and enzyme activity of CPT1A. In contrast, PGC1α knockdown HONE1 and C666-1 cells showed decreased CPT1A mRNA, protein levels and enzyme activity ( Figure 3A-C) .
We further analyzed the relationship between PGC1α and CPT1A expression in a tissue microarray comprised of non-keratinizing undifferentiated NPC patients following radiation therapy by IHC (n = 47). Representative photos are shown in Figure 3D . Double high expression for PGC1α and CPT1A was observed in 75% (15/20) and double low expression accounted for 74% (20/27) of the patient samples ( Figure 3E ). Co-expression analysis of the IHC scores for
PGC1α and CPT1A with a Spearman correlation test showed that a positive correlation existed between PGC1α and CPT1A expression in the NPC tissues ( Figure 3F ). These data suggest that PGC1α positively regulates CPT1A in NPC cell lines and patient tissues. 
| PGC1α and CEBPB form a complex and bind to the promoter of CPT1A
Then we used online prediction and a co-immunoprecipitation assay to examine whether PGC1α binds to CEBPB. We analyzed The combination of PGC1α and CEBPB showed a more significant increase in luciferase activity. Moreover, the increase in CPT1A
promoter activity by PGC1α overexpression could be cancelled by silencing CEBPB. In addition, the increase in CPT1A promoter activity by CEBPB overexpression could be cancelled by PGC1α knockdown ( Figure 5D ). Initially, we identified putative CEBPB binding sites in the CPT1A promoter through bioinformatics analysis and designed 4 primers for these possible binding sites. promoter ( Figure 5E ). These data suggest that PGC1α interacts with CEBPB to activate CPT1A.
| The PGC1α/CEBPB/CPT1A signaling axis promotes radiation resistance of nasopharyngeal carcinoma cells
We further hypothesized that PGC1α/CEBPB/CPT1A could pro- 
| D ISCUSS I ON
Previous studies showed that abnormal expression of PGC1α is associated with cancer resistance to therapy. CEBPB plays an important role in cell proliferation and differentiation, metabolism, and inflammation. 40, 54, 55 In the regenerating liver of mice, CPT1A was decreased after CEBPB was knocked out.
56
CEBPB is closely related with lipid metabolism in HepG2 cells and liver cancer cells. 57, 58 CEBPB expression is associated with overall survival in breast cancer and gastric cancer patients. 59, 60 In Ewing sarcoma and ovarian cancer, CEBPB could promote tumor cell resistance to chemotherapy. 61, 62 In this study, we found that CEBPB promotes the transcription of CPT1A and activates FAO. We confirmed that PGC1α binds to CEBPB and is co-localized to the promoter of CPT1A; knockdown of CEBPB sensitized NPC cells to radiation therapy. However, the precise mechanism of the PGC1α-CEBPB interaction is not clear.
Interestingly, we observed an increased expression of CEBPB in PGC1α-overexpressing HK1 cells. CEBPB has been shown to regulate the expression of the PGC1α gene by binding to a cAMP response element in the PGC1α promoter. 63 The reduced transcriptional activity of CEBPB inhibits PGC1α expression. 64 Thus, a complicated feedback loop between PGC1α and CEBPB might exist under different circumstances.
Overall, our study showed that the PGC1α-CEBPB interaction positively regulates CPT1A, which can facilitate FAO, and maximizes ATP and NADPH production, contributing to radiation resistance.
The expression of PGC1α could be a prognostic indicator of NPC.
Targeting the PGC1α/CEBPB/CPT1A signaling axis might be a potential strategy to improve the therapeutic efficacy of radiotherapy in NPC.
F I G U R E 7 A schematic to illustrate PGC1α-mediated radiation resistance in nasopharyngeal carcinoma (NPC). The activation of PGC1α and the PGC1α-CEBPB interaction promote the transcription, expression and enzyme activity of CPT1A, which facilitates fatty acid oxidation and maximizes ATP and NADPH production, leading to resistance to radiation 
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